Slide 1: Investors' and Analysts' Conference Call FY 2020
INVESTORS’ AND ANALYSTS’ CONFERENCE CALL FY 2020 Grünwald, 13 April 2021
Slide 2: Disclaimer
Disclaimer This publication includes statements, estimates, opinions and projections with respect to the anticipated future performance of Dermapharm Holding SE (together with its consolidated subsidiaries, “Dermapharm”) and such statements, estimates, opinions and projections (“Forward- Looking Sta
Slide 3: Agenda
AGENDA 1. Highlights FY 2020 2. Financial figures FY 2020 3. Outlook FY 2021 4. Q & A
Slide 4: Agenda
AGENDA 1. Highlights FY 2020 2. Financial figures FY 2020 3. Outlook FY 2021 4. Q & A
Slide 5: Highlights FYR 2020: Dermapharm provides resilience in a challenging year
Highlights FYR 2020 Dermapharm provides resilience in a challenging year COVID-19 pandemic Dermapharm’s business model proved to be crisis-proof and adaptable – continuous ability to produce and deliver at all production sites Allergopharma Successful acquisition and integration into Dermapharm Grou
Slide 6: Highlights FYR 2020 – COVID-19 pandemic
Highlights FYR 2020 – COVID-19 pandemic Dermapharm’s business model proved to be crisis-proof and adaptable Flexibility ensured ability to meet demand for products at all Production in Germany times and to avoid supply bottlenecks Risks in submarkets could be compensated by opportunities in Broad pr
Slide 7: Highlights FYR 2020 – Integration of Allergopharma
Highlights FYR 2020 – Integration of Allergopharma Restructuring measures and lifting of synergy potentials are bearing fruits Diagnosis for tailored treatment of allergies Portfolio of Allergy Immunotherapy (AIT) products Allergovit® Acaroid® Novo-Helisen® Headquarter in Reinbek, Germany Presence i
Slide 8: Highlights FYR 2020 – Vaccine production
Highlights FYR 2020 – Vaccine production… … based on cooperation and delivery agreement with BioNTech BioNTech Dermapharm mRNA Lipid mRNA nanoparticles Step 1 + 2 Step 3 Step 4 Cold storage Production and Lipid nanoparticles are Filling of the Creation purification of necessary transportation vaccin
Slide 9: Highlights FYR 2020 – Strategy
Highlights FYR 2020 – Strategy Consequent implementation of Dermapharm’s three-pillar-strategy Pipeline of > 50 ongoing development projects with six In-house successful new product launches in 2020 development Herbal extracts – development of new phyto extracts Regional expansion by Allergoph
Slide 10: Agenda
AGENDA 1. Highlights FY 2020 2. Financial figures FY 2020 3. Outlook FY 2021 4. Q & A
Slide 11: Delivering on our guidance 2020 – targets overachieved
Highlights FYR 2020 Delivering on our guidance 2020 – targets overachieved despite challenging developments Guidance 2020 FYR 2020 Revenues + 12% to + 15% vs. previous year (€700.9m) + 13.0% (€793.8m) EBITDA(1) (adjusted) + 8% to + 10% vs. previous year (€177.6m) + 13.0% (€200.7m) Note: (1) EBIT
Slide 12: Dermapharm Group: Further growth despite difficult COVID-19 circumstances
Dermapharm Group Further growth despite difficult COVID-19 circumstances Total Revenue (€m) EBITDA(1) (€m, adjusted) Comments EBITDA Margin +13.3% YoY 25.3% 25.3% High revenue growth of 13.3% to €793.8m, due to 793.8 revenue driven by acquisitions and COVID-19 vaccine 700.9 production significan
Slide 13: Branded pharmaceuticals and other healthcare products
Branded pharmaceuticals and other healthcare products Strong growth due to integration of acquisition Revenue (€m) EBITDA(1) (€m, adjusted) Comments EBITDA Margin +22.4% YoY 41.1% 39.1% Revenues increased by 22.4% to €471.3m mainly caused by integration of Fitvia and Allergopharma huge growth in
Slide 14: Parallel import business
Parallel import business Higher market share in slightly decreasing PI market Revenue (€m) EBITDA (€m) Comments EBITDA Margin +2.9% YoY 3.4% 2.8% Revenues increased by 2.9% to €250.6m demand for parallel imported originator products was flattening out increased market share in slightly decreasin
Slide 15: Herbal extracts
Herbal extracts Lower demand due to COVID-19 pandemic Revenue (€m) EBITDA(1) (€m, adjusted) Comments EBITDA Margin -0.6% YoY 22.7% 21.1% Revenues decreased by 0.6% to €71.9m, consisting of Euromed global demand for herbal extracts went down 71.9 because of COVID-19 pandemic and could not be compen
Slide 16: Earnings before tax (Group EBT)
Earnings before tax (Group EBT) Result increased due to M&A and business growth Earnings before tax (EBT)(1) (€m) Comments EBT Margin 15.7% 15.8% EBT increased by 13.8% to €125.3m (unadjusted) resulting in a margin of 15.8% +13.8% YoY Mainly influenced by 125.3 Slightly lower depreciation and am
Slide 17: Strong cash flows and cash conversion
Strong cash flows and cash conversion Reflecting strong dedication to future growth Cash flow and cash conversion(1)(€m) Comments in % of Group EBITDA Cash conversion 57.1% 65.4% CF from operating activities increased mainly influenced by increased EBT in FY 2020 and decreased tax payments C
Slide 18: Balance sheet of Dermapharm Group
Balance sheet of Dermapharm Group Balance Sheet as of 31 December 2020 (€m) Comments Total assets increased to €1,224m (31 December 2019: €1,045m) 1,224 1,224 Non-current assets amount to €824m (31 December 2019: €692m) caused by integration of Allergopharma Current assets grew to €400m 325 Eq
Slide 19: Agenda
AGENDA 1. Highlights FY 2020 2. Financial figures FY 2020 3. Outlook FY 2021 4. Q & A
Slide 20: Outlook 2021
Outlook 2021 Growth strategy on track positive growth of 24 - 26% Revenues 2021 vs. previous year (€793.8m) EBITDA 2021 positive growth of 45 - 50% (adjusted) vs. previous year (€200.7m) Growth rates are based on organic growth supported by new launches of in-house developments. Guidance for the fin
Slide 21: Agenda
AGENDA 1. Highlights FY 2020 2. Financial figures FY 2020 3. Outlook FY 2021 4. Q & A
Slide 22: For information, please contact
For information, please contact Britta Hamberger Investor Relations & Corporate Communications Dermapharm Holding SE E-Mail: ir@dermapharm.com Phone: +49 (0) 89 641 86 233